Glenmark Pharmaceuticals Limited — Updates, 20-03-2025: Press Release

Glenmark Pharmaceuticals has received final approval from the U.S. FDA for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), deemed bioequivalent to Alcon's Pataday® Once Daily Relief. This product will be distributed in the U.S. by Glenmark Therapeutics Inc. According to recent market data, the Pataday® solution recorded annual sales of approximately $50.7 million. Glenmark's expansion into the OTC ophthalmic segment reflects its commitment to fulfilling market demands and enhancing its portfolio. This development not only reinforces Glenmark's position in the ophthalmic market but also presents a potential growth opportunity as it seeks to capture market share in this lucrative space. Investors should keep an eye on how this product launch contributes to overall sales and company performance.